Geneva, April 28 -- International Clinical Trials Registry received information related to the study (ChiCTR2600122483) titled 'A study of benmelstobart, anlotinib, chemotherapy and thoracic radiotherapy for people with extensive-stage small cell lung cancer' on April 14.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Shanghai Pulmonary Hospital
Condition:
Extensive-Stage Small Cell Lung Cancer
Intervention:
Single Arm:Bemotuzumab Vedotin Injection 1200mg intravenous infusion every 3 weeks + Anlotinib Hydrochloride Capsules 12mg oral once daily (continuous 2 weeks, then 1 week off) + Carboplatin AUC 5 mg/mL/min intravenous infusion on day 1 + Cisplatin 75-80 mg/m2 intravenous infusion on day 1 + Etoposi...